Raynaud's phenomenon possibly induced by a compound drug of tegafur and uracil

European Journal of Dermatology

Volumn 10, Issue 1, 2000, Pages 55-58

  Seishima, Mariko ^a   Izumi, Tomoko ^a   Kanoh, Hiroyuki ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Antinuclear antibody; Raynaud's phenomenon; Sclerodactyly; Tegafur

Indexed keywords

ANTINUCLEAR ANTIBODY; CAMOSTAT MESILATE; CISAPRIDE; UFT;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CELL INFILTRATION; DRUG INDUCED DISEASE; ERYTHEMA; FEMALE; HALLUX RIGIDUS; HUMAN; HYPERPIGMENTATION; KERATOSIS PALMOPLANTARIS; RAYNAUD PHENOMENON; STOMACH ADENOCARCINOMA; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTINUCLEAR; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; HUMANS; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; TEGAFUR; URACIL;

EID: 0033968022     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 1. Marik STA, Talbot D, Clarke PI, Osborne R, Reznek R, Wrigley PFM, Slevin ML. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990; 62: 1023-5.
2. 2. Maehara Y, Takeuchi H, Oshiro T, Takahashi I, Inutsuka S, Baba H, Kohnoe S, Sugimachi K. Effect of gastrectomy on the pharmacokinetics of tegafur, uracil and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination. Cancer Chemother Pharmacol 1994; 33: 445-9.
3. 3. Won YH, Seo JJ, Kim SJ, Lee SC, Chen IK. Knuckle pad-like keratoderma: a new cutaneous side reaction induced by tegafur. Int J Dermatol 1998; 37: 315-8.
4. 4. Bastida J, Diaz-Cascajo C, Borghi S. Chemotherapy-induced acral erythema due to tegafur. Acta Derm Venereol (Stockh) 1997; 77: 72-3.
5. 5. Rios-Buceta L, Buezo GF, Peñas PF, Dauden E, Fernandez-Herrera J, Garcia-Diez A. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with tegafur. Acta Derm Venereol (Stockh) 1997; 77: 80-1.
6. 6. Akiyama C, Osada A, Sou K, Yasaka N, Ohtake N, Furue M, Tamaki K. A Case of dermatomyositis triggered by tegafur. Acta Derm Venereol (Stockh) 1997; 77: 490.
7. 7. Usuki A, Funasaka Y, Oka M, Ichihashi M. Tegafur-induced photosensitivity-evaluation of provocation by UVB irradiation. Int J Dermatol 1997; 36: 604-18.
8. 8. Bedikian AY, Stroenhlein J, Korinek J, Karlin D, Bodey GP. A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. Am J Clin Oncol 1983; 6: 181-6.
9. 9. LeRoy EC, Black C, Fleishmajer R, Jablonska S, Krieg TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
10. 10. Llistosella E, Codina A, Alvarez R, Pujuol RM, Moragas JM. Tegafur-induced acral hyperpigmentation. Cutis 1991; 48: 205-7.
11. 11. Jucgla A, Sais G. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131: 364-5.
12. 12. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Int Med 1984; 101: 798-800.
13. 13. Vukelja SJ, Bonner MW, McCollough M, Cobb PW, Gaule DA, Fanucchi PJ, Keeling JH. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. J Am Acad Dermatol 1991; 25: 905-8.
14. 14. Vukelja SJ, James WD, Weiss RB. Severe dermatologic toxicity from 5-fluorouracil in the presence of seborrheic dermatitis. Int J Dermatol 1989; 28: 353-4.
15. 15. Dudley K, Micetich K, Massa MC. Erythema with features of seborrheic dermatitis and lupus erythematosus associated with systemic 5-fluorouracil. Cutis 1987; 39: 64-6.
16. 16. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Int Med 1981; 95: 288-92.
17. 17. Bellmunt J, Navarro M, Morales S, Jolis L, Carulla J, Knobell H, Vilardell M, Sole LA. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer 1990; 65: 303-9.